Ernst Guenter Afting Net Worth

The estimated Net Worth of Ernst Guenter Afting is at least $555 millier dollars as of 11 December 2013. Ernst Afting owns over 15,000 units of Sorrento Therapeutics Inc stock worth over $173 and over the last 15 years Ernst sold SRNE stock worth over $554,700.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ernst Afting SRNE stock SEC Form 4 insiders trading

Ernst has made over 2 trades of the Sorrento Therapeutics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Ernst sold 15,000 units of SRNE stock worth $554,700 on 11 December 2013.

The largest trade Ernst's ever made was buying 360,000 units of Sorrento Therapeutics Inc stock on 21 December 2010 worth over $50,400. On average, Ernst trades about 34,091 units every 99 days since 2010. As of 11 December 2013 Ernst still owns at least 17,287 units of Sorrento Therapeutics Inc stock.

You can see the complete history of Ernst Afting stock trades at the bottom of the page.

What's Ernst Afting's mailing address?

Ernst's mailing address filed with the SEC is C/O SORRENTO THERAPEUTICS, INC., 6042 CORNERSTONE COURT WEST, SUITE B, SAN DIEGO, CA, 92121.

Insiders trading at Sorrento Therapeutics Inc

Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee et Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.

What does Sorrento Therapeutics Inc do?

sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.

Complete history of Ernst Afting stock trades at Enanta Pharmaceuticals Inc et Sorrento Therapeutics Inc

Sorrento Therapeutics Inc executives and stock owners

Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jaisim Shah,
  Director
• Henry Ji,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Dr. Henry H. Ji Ph.D.,
  Chairman, Pres & CEO
• Najjam Asghar,
  Sr. VP & CFO
• Kim Janda,
  Director
• Yue Wu,
  Independent Director
• Dorman Followwill,
  Lead Independent Director
• David Lemus,
  Independent Director
• Robin Smith,
  Independent Director
• Edgar Lee,
  Independent Director
• Najjam Asghar,
  Chief Financial Officer
• William J. Farley,
  VP of Sales & Bus. Devel.
• Dr. Robert D. Allen Ph.D.,
  Sr. VP of Antiviral & Immunotherapy
• Brian Cooley,
  Sr. VP of Lymphatic Drug Delivery BU Leader
• Dr. Shawn Sahebi Ph.D.,
  Sr. VP of Strategy & Analytics
• Dr. Mark R. Brunswick,
  Sr. VP of Regulatory Affairs
• Dr. Alexis Nahama,
  Sr. VP & Head of RTX Program
• Dr. Michael A. Royal,
  SVP & Chief Medical Officer
• Bill Farley,
  VP of Sales & Bus. Devel.
• Brian Sun,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Jane Ph D Hsiao,
  Director
• Management Ltd Abg Srne Ltd...,
  
• Douglas O Ebersole,
  Director
• Jeffrey Su,
  Executive VP and COO
• Kevin Herde,
  Executive VP and CFO
• William S Marth,
  Director
• Management Ltd Abg Srne Ltd...,
  
• George K Ng,
  See Remarks
• Patrick Chan Soon Shiong Fa...,
  
• Jerome B Zeldis,
  See Remarks
• David H Deming,
  Director
• Antonius Schuh,
  Chairman and CEO
• Steve Zaniboni,
  Director
• Curtis Lockshin,
  Director
• Donald R Scifres,
  10% owner
• Diane D S Tang Liu,
  Director
• Glenn L Halpryn,
  Director
• Charles P Rodi,
  VP, Research & Development
• Martina Molsbergen,
  VP, Business Development
• Dean Ferrigno,
  Chief Accounting Officer
• Pacific Med Tech (Bvi) Ltd ...,
  
• Management Ltd Abg Srne Ltd...,
  
• Management Ltd Abg Ii So Lt...,
  
• Jiong Shao,
  Chief Financial Officer
• Zhenwei Miao,
  Chief Technology Officer
• George Uy,
  Chief Commercial Officer
• Patrickmp 13 Ventures, Llc ...,
  
• Michael Scott Salka,
  Director
• Health, Inc. Opko,
  10% owner
• Mark Durand,
  Director
• Richard G Vincent,
  Chief Financial Officer
• Cam Gallagher,
  Director
• David Ritchie Webb,
  Director
• Ernst Guenter Afting,
  Director
• Vuong Trieu,
  CSO
• Elizabeth Czerepak,
  EVP & Chief Financial Officer
• Tammy Reilly,
  Director